Chong Kun Dang Pharmaceutical
Clinical trials sponsored by Chong Kun Dang Pharmaceutical, explained in plain language.
Pharmaceutical company producing prescription drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cheaper psoriasis drug on the horizon? new biosimilar enters human trials Results expected Sep 2026 (estimated)
- Can a new blood pressure pill match the original? Results expected Oct 2026 (estimated)
- New biosimilar aims to offer cheaper eczema treatment Results expected Nov 2026 (estimated)
- New hope for advanced cancer patients: experimental drug CKD-512 enters human trials Results expected Mar 2027 (estimated)
- New drug combo for BRCA ovarian cancer enters early testing Results expected Jun 2027 (estimated)